“Our thesis relies in part on a successful Icotyde launch, which we view as a potential $10B+ peak sales opportunity,”

UBS · said 2026-09-02 · reported 2026-09-03

UBS analysts view Icotyde, J&J's newly approved oral IL-23 inhibitor, as a key part of their bullish thesis.